Aditxt(ADTX) Shares Plunge 13.19% Amid Mayo Clinic Study Findings

Aditxt(ADTX) shares plummeted 13.19% today, marking the lowest level since March 2025, with an intraday decline of 14.93%.

The recent findings from the Mayo Clinic study have significantly impacted Aditxt's stock price. The study confirmed the safety and efficacy of ADI-100, Aditxt's investigational therapy for multiple autoimmune conditions. This validation underscores the potential of ADI-100 in treating autoimmune diseases, which could positively influence investor sentiment and stock performance. The positive results from the study have provided a strong foundation for the company's future prospects, as regulatory submissions for ADI-100 are planned for 2025. This forward-looking impact is expected to drive further developments and potentially boost the company's market position.